Sparing early stage patients with hodgkin lymphoma

Access through your institution Buy or subscribe Although more than 1,000 children and adolescents will be diagnosed with Hodgkin lymphoma this year in the USA, about 90% of these patients

can expect to achieve long-term cures after receiving modern multimodality therapies. This impressive cure rate stems from the use of aggressive chemotherapy regimens, coupled with

radiotherapy, but it comes at the price of adverse effects that can affect patients throughout their lives. As Monika Metzger points out in a _Jounal of Clinical Oncology_ podcast: “this

rapidly growing population of childhood cancer survivors will suffer lifelong consequences and late effects of therapy... Ageing survivors are at risk of cardiopulmonary dysfunction and

secondary malignancies, the leading causes of death more than 10 years after the original diagnosis.” With the acknowledgement of the importance of these late effects has come a shift in

clinical trials in these patients, with the aim being to spare patients from therapy while maintaining efficacy. One such study is the GPOH-HD95 trial, led by Wolfgang Dörffel, which aimed

to minimize the risk of late effects by omitting radiotherapy in patients who were in complete remission after chemotherapy. This trial was initiated in 1995, and recruited 925 patients with

classic Hodgkin lymphoma. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print

issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to

local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support ORIGINAL RESEARCH

PAPER * Dörffel, W. _ et al_. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the

multinational trial GPOH-HD95. _J. Clin. Oncol._ doi:10.1200/JCO.2012.45.3266 Download references Authors * Rebecca Kirk View author publications You can also search for this author inPubMed

 Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Kirk, R. Sparing early stage patients with Hodgkin lymphoma. _Nat Rev Clin Oncol_ 10, 248

(2013). https://doi.org/10.1038/nrclinonc.2013.50 Download citation * Published: 02 April 2013 * Issue Date: May 2013 * DOI: https://doi.org/10.1038/nrclinonc.2013.50 SHARE THIS ARTICLE

Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided

by the Springer Nature SharedIt content-sharing initiative